Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Franks

Showing results (251-260 of 287) with videos related to

Pageof 29
Sort By:
Molecular Biotherapy|March 1, 1990
Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient studyJ Atzpodien, A Körfer, P Evers, et al.
Pharmacotherapy|June 28, 2005
Gender differences in the use of peak flow meters and their effect on peak expiratory flowTimothy H Self, L Brian Cross, Shambria E Nolan, et al.
Cancer|April 1, 1991
The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2H Kirchner, A Körfer, P Evers, et al.
European Cytokine Network|August 1, 1990
Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapyM Favrot, R Capdeville, V Combaret, et al.
Scientific Reports|July 9, 2015
How ants use quorum sensing to estimate the average quality of a fluctuating resourceNigel R Franks, Jonathan P Stuttard, Carolina Doran, et al.
Journal of Biological Response Modifiers|April 1, 1990
Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinomaM C Favrot, V Combaret, S Negrier, et al.
Pediatric Hematology and Oncology|January 1, 1990
Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantationM C Favrot, J Michon, D Floret, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinomaS D Heys, O Eremin, E M Ruggeri, et al.
Schizophrenia Bulletin|January 1, 1987
Neurobiological studies of sensory gating in schizophreniaR Freedman, L E Adler, G A Gerhardt, et al.
British Journal of Haematology|October 1, 1990
Increased numbers of circulating haematopoietic progenitor cells after treatment with high-dose interleukin-2 in cancer patientsM R Schaafsma, W E Fibbe, D van der Harst, et al.
Pageof 29

Showing results (251-260 of 287) with videos related to

Sort By:
Pageof 29
Molecular Biotherapy|March 1, 1990
Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient studyJ Atzpodien, A Körfer, P Evers, et al.
Pharmacotherapy|June 28, 2005
Gender differences in the use of peak flow meters and their effect on peak expiratory flowTimothy H Self, L Brian Cross, Shambria E Nolan, et al.
Cancer|April 1, 1991
The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2H Kirchner, A Körfer, P Evers, et al.
European Cytokine Network|August 1, 1990
Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapyM Favrot, R Capdeville, V Combaret, et al.
Scientific Reports|July 9, 2015
How ants use quorum sensing to estimate the average quality of a fluctuating resourceNigel R Franks, Jonathan P Stuttard, Carolina Doran, et al.
Journal of Biological Response Modifiers|April 1, 1990
Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinomaM C Favrot, V Combaret, S Negrier, et al.
Pediatric Hematology and Oncology|January 1, 1990
Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantationM C Favrot, J Michon, D Floret, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinomaS D Heys, O Eremin, E M Ruggeri, et al.
Schizophrenia Bulletin|January 1, 1987
Neurobiological studies of sensory gating in schizophreniaR Freedman, L E Adler, G A Gerhardt, et al.
British Journal of Haematology|October 1, 1990
Increased numbers of circulating haematopoietic progenitor cells after treatment with high-dose interleukin-2 in cancer patientsM R Schaafsma, W E Fibbe, D van der Harst, et al.
Pageof 29